Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ED50 and safety of remimazolam + nalbuphine for painless gastroscopy in elderly patients
ChiCTR2100054347Phase 4Completed
- Sponsor
- The First Affiliated Hospital, Anhui Medical University
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of remimazolam in None, sponsored by The First Affiliated Hospital, Anhui Medical University. Primary endpoints: Median effective dose (ED50) of remimazolam and Orientation recovery time. Started Jan 2022; status: completed.
02
Drugs
remimazolam
Beyond the preview
Go deeper on ChiCTR2100054347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100054347.